Author/Authors :
Zhou، نويسنده , , Wei and Wang، نويسنده , , Li and Gou، نويسنده , , Shan-miao and Wang، نويسنده , , Tong-ling and Zhang، نويسنده , , Meng and Liu، نويسنده , , Tao and Wang، نويسنده , , Chun-you، نويسنده ,
Abstract :
Glycogen synthase kinase-3 beta (GSK-3β), a serine/threonine protein kinase, plays a vital role in the tumorigenesis of many cancers, but its role in pancreatic cancer remains unknown. In this study, we showed that GSK-3β was aberrantly activated in pancreatic cancer. GSK-3β knockdown resulted in arrested proliferation and increased apoptosis in pancreatic cancer cell lines. Expression of Bcl-2 and vascular endothelial growth factor (VEGF) decreased significantly in a GSK-3β knockdown group. In a xenograft tumor model, GSK-3β knockdown inhibited tumor growth and angiogenesis. Our study showed that GSK-3β may become a promising therapeutic target for human pancreatic cancer.
Keywords :
RNA interference , GSK-3? , Molecular targeted therapy , Pancreatic neoplasia
